Correction to: Acacia hydaspica R. Parker ameliorates cisplatin induced oxidative stress, DNA damage and morphological alterations in rat pulmonary tissue

Abstract

Correction to: BMC Complement Altern Med (2018) 18:49 https://doi.org/10.1186/s12906-018-2113-0 Following publication of the original article [1], the author reported that Tables 3 and 4 were incorrect due to a production error. Table 3 Effect of cisplatin (CP) and different treatments of AHE on lung tissue antioxidant enzymes Group POD(U/min) SOD(U/mg protein) CAT(U/min) QR(nM/min/mg protein) Control 9.56 ± 0.635b 1.366 ± 0.038b 18.48 ± 0.058b 128.2 ± 0.81b CP 5.03 ± 0.271a 0.765 ± 0.019a 10.83 ± 0.049a 83.99 ± 0.486a AHE alone 10.29 ± 0.314b 1.358 ± 0.058b 18.57 ± 0.057b 128.9 ± 0.179b CP + AHE 6.22 ± 0.128a, d 0.982 ± 0.035a,b*,d** 14.15 ± 0.083a,b, d 98.82 ± 1.232a.b, d AHE + CP 9.18 ± 0.185b, c 1.255 ± 0.038b,c** 17.07 ± 0.026a,b, c 119.5 ± 1.283a,b, c CP + Sily 9.20 ± 0.208b 1.262 ± 0.021b 17.14 ± 0.081a,b 119.9 ± 1.008a,b Values expressed as mean ± SEM. a Significance at p < 0.0001 Vs. control group, b Significance at p < 0.0001 Vs. Cisplatin (CP) group. c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group. d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group. *, **: Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests) Table 4 Effect of cisplatin (CP) and different treatments of AHE on lungs tissue antioxidant enzymes and GSH profile Group GSH(μM/g tissue) GR(nM/min/mg protein) GST(nM/min/mg protein) γ-GT(nM/min/mg Protein) GPx(nM/min/mg Protein) Control 16.12 ± 0.578b 143.7 ± 1.342b 98.85 ± 0.918b 295.4 ± 1.113b 107.4 ± 0.730b CP 8.334 ± 0.356a 98.02 ± 0.619a 68.17 ± 0.962a 82.82 ± 0.958a 54.08 ± 0.909a AHE alone 6.38 ± 0.207b 144.0 ± 1.492b 99.79 ± 1.865 b 295.6 ± 0.599b 108.8 ± 1.216b CP + AHE 11.99 ± 0.305a,b, d 116.9 ± 0.813a,b,d 78.34 ± 1.076a,b**,d** 137.8 ± 1.017a,b,d 71.28.8 ± 0.501a,b,c AHE + CP 15.63 ± 0.532b, c 135.0 ± 0.393 a,b,c 89.65 ± 1.49 a**,b,c 261.4 ± 0.802a,b,c 92.78 ± 1.216a,b,c CP + Sily 15.29 ± 0.312b 133.8 ± 1.25 a,b 87.60 ± 1.644a,b 264.3 ± 1.067a,b 95.64 ± 1.573a,b Values expressed as mean ± SEM. a Significance at p < 0.0001 Vs. control group, b Significance at p < 0.0001 Vs. Cisplatin (CP) group. c Significance at p < 0.0001 of AHE + CP pre-treated group Vs. CP + AHE post-treated group. d Significance at p < 0.0001 of CP + AHE treatment groups Vs CP + Sily group. *, **: Significant difference at p < 0.001. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters (One way ANOVA followed by Tukey’s multiple comparison tests) The corrected tables are given below.